Insufficient signaling through single-pathway kinase inhibition limits therapeutic efficacy. Overcoming this threshold increases potency in complex immune-mediated pathologies.

Rapid systemic clearance and metabolic instability of natriuretic peptides. Extending biological persistence enables sustained therapeutic efficacy.

Acquired resistance and metabolic clearance limit the efficacy of single-agent therapies. Overcoming these barriers prevents disease progression and improves patient survival rates.

Low binding affinity and rapid clearance of monomeric tracers limit diagnostic sensitivity and therapeutic efficacy. Increasing valency through multimeric structures overcomes poor target residence time.